Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
13 January 2020 - Posted by: Eda Zhuleku
The Digital Healthcare Act (Digitale-Versorgung-Gesetz DVG) was published in the German Federal Law Gazette (Bundesgesetzblatt) on 18 December 2019 and entered into force on 19 December 2019, having been passed by the German Parliament (Bundestag) in November 2019. Among other regulations intended to expand the digitalisation of the healthcare system, the law will allow the › Read More
07 January 2020 - Posted by: Eveline Van Keymeulen
On 19 November 2019, pursuant to Article 66 of the 2019 Social Security Financing Act (LFSS), the implementing order that indicates the medical situations in which physicians may exclude substitution on prescriptions was published (Order of 12 November 2019). For background information, see our previous blog post French 2019 Social Security Financing Act introduces new › Read More
03 January 2020 - Posted by: Matthew Appleton
At a time of heightened regulatory and market uncertainty, it’s perhaps surprising to see life sciences and healthcare sector M&A continuing to grow so strongly. Indeed, with deal value up by more than 19%, it was one of only two sectors to record growth in transaction value. Not surprisingly, given the scale of the U.S. › Read More
20 December 2019 - Posted by: Sophie van Asten
On 4 November 2019, the Dutch Minister of Care wrote a letter to the House of Representatives, proposing a solution for medicine shortages. In order to prevent shortages, additional stocks of medicines should be built up by obliging medicine manufacturers and wholesalers to build up mandatory buffers (“base stocks”) of five months’ duration, starting in › Read More
18 December 2019 - Posted by: Jeanne Fabre
In accordance with Article 66 of the 2019 Social Security Financing Bill (PLFSS), the details of the hybrid medicines register have been published through a decree on 20 November 2019 (see our previous blog post: French 2019 Social Security Financing Act introduces new healthcare measures). Decree No 20169-1192 specifies the registration procedure and removal of › Read More